Casey Vanhoose
Physician Assistant · White House, TNNPI 1144890682
Payments from drug & device makers
Across 242 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$926
- AbbVie$780
- Pfizer$394
- Lilly USA, LLC$390
- AstraZeneca$305
- Astellas Pharma US Inc$267
- plus $1K from 27 others
What the payments were for
- Food & beverage$4,38399%
- Education$661%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 44 | $926 |
| AbbVie | 42 | $780 |
| Pfizer | 23 | $394 |
| Lilly USA, LLC | 35 | $390 |
| AstraZeneca | 10 | $305 |
| Astellas Pharma US Inc | 12 | $267 |
| Otsuka America Pharmaceutical, Inc. | 12 | $230 |
| Exact Sciences | 15 | $195 |
| GSK | 10 | $163 |
| Phathom Pharmaceuticals, Inc. | 7 | $119 |
| Corcept Therapeutics | 3 | $68 |
| Boston Scientific | 2 | $59 |
| Inspire Medical Systems, Inc. | 1 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Lundbeck LLC | 2 | $40 |
| Axsome Therapeutics, Inc. | 1 | $35 |
| Johnson & Johnson(2 entities) | 2 | $35 |
| Boehringer Ingelheim | 2 | $33 |
| Sumitomo Pharma America, Inc. | 2 | $32 |
| Ultragenyx Pharmaceutical Inc. | 1 | $30 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $28 |
| Averitas Pharma Inc. | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Nevro Corp. | 1 | $21 |
| Philips North America LLC | 1 | $21 |
| Seqirus USA Inc | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Radius Health, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Tolmar, Inc. | 1 | $16 |
| Merck | 1 | $14 |
| Antares Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,449 in reported general payments places this provider in the 85th percentile of 2,404 physician assistant providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 64 | $72,419 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $40,090 |
| MounjaroTirzepatide | 19 | $19,372 |
| FarxigaDapagliflozin Propanediol | 23 | $18,191 |
| EliquisApixaban | 11 | $12,394 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $11,587 |
| MyrbetriqMirabegron | 13 | $10,891 |
| JardianceEmpagliflozin | 11 | $10,807 |
| GemtesaVibegron | 13 | $8,306 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 64 | $2,107 |
| Gabapentin | 48 | $990 |
| Rosuvastatin Calcium | 68 | $973 |
| Fluticasone Propionate | 82 | $954 |
| Azelastine Hcl | 24 | $827 |
| Atorvastatin Calcium | 65 | $730 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $926 | $72,41964 claims |
| GSKTrelegy Ellipta | $163 | $40,09041 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $305 | $29,77838 claims |
| Lilly USA, LLCMounjaro, Humalog | $390 | $20,02131 claims |
| PfizerEliquis | $394 | $12,39411 claims |
| Astellas Pharma US IncMyrbetriq | $267 | $10,89113 claims |
| Boehringer IngelheimJardiance | $33 | $10,80711 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $32 | $8,30613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,404 physician assistant providers in Tennessee.
Other physician assistant in White House
- Lindsey NixKnoxville$576K
- Anna KerseySavannah$399K
- Jason HenryNashville$329K
- Brie ChandlerNashville$317K
- Loree EasleyBartlett$209K
- Katherine RunyanKnoxville$156K
- John KramerNashville$125K
- Robert LaughertyAlcoa$122K
- Elisabeth BennettNashville$109K
- Whitney GatewoodMemphis$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.